Apolipoprotein D is associated with long-term outcome in patients with schizophrenia

Thomas F Hansen, R P Hemmingsen, August G. Wang, L Olsen, S Timm, Karen Søeby, K D Jakobsen, M Fenger, J Parnas, Henrik Berg Rasmussen, Thomas Werge

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Accumulating evidence implicates deficiencies in apolipoprotein D (ApoD) function and arachidonic acid signaling in schizophrenic disorders. We addressed two hypotheses in relation to ApoD: first, polymorphisms in the ApoD gene confer susceptibility to or are markers of disease, and, second, genetic variation in the ApoD is associated with long-term clinical outcome to antipsychotic treatment. We genotyped two single-nucleotide polymorphisms in the ApoD gene in 343 chronic patients with schizophrenia spectrum disorders (ICD-10) and 346 control subjects of Danish origin. We did not find ApoD alleles, genotypes or haplotypes to be associated with disease. However, we did find that long-term clinical outcome was associated with the ApoD polymorphism rs7659 (P = 0.041) following adjustment for lifetime clinical global impression, age at first admission and gender.
Original languageEnglish
Pages (from-to)120-125
Number of pages6
JournalPharmacogenomics Journal
Issue number2
Publication statusPublished - 2006


  • adult
  • antipsychotic agents
  • apolipoproteins D
  • case-control studies
  • DNA
  • female
  • genetic predisposition ti disease
  • humans
  • logistic models
  • male
  • middle aged
  • multivariate analysis
  • polymorphism
  • single nucleotide
  • risk factors
  • schizophrenia
  • time factors
  • treatment outcome
  • chronic schizophrenia
  • clozapine
  • treatment refractory
  • lipid metabolism
  • neurodegeneration
  • long-term outcome


Dive into the research topics of 'Apolipoprotein D is associated with long-term outcome in patients with schizophrenia'. Together they form a unique fingerprint.

Cite this